Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's a scam, IMHO. More secondary to come and it never ends..
Just sell on news. Will go back on an uptrend. Give it some time.
No one disputes that the results were very good albeit preliminary.
TGTX PT raised to $19 frm $13 at Brean.
Well we all play games but the potential of Zalviso uptake in hospitals should not be under estimated. With Europe partnership adoption will rapidly expand.
I recommend everyone to watch to video on ACRX website as well.
$15+ minimum upon approval.
Great piece on ACRX by none other than AF on his Friday mailbag.
http://www.thestreet.com/story/12775982/1/biotech-stock-mailbag-acelrx-yellen-aftermath-nymox.html
I have marked your post for a good laugh come next week. Thanks for enlightening us.
Thanks for the book recommendation. While I tend to invest for LT, often I am troubled on risk vs reward which includes saving on CGT. This year paid dearly to Uncle Sam for TSRX acquisition by CBST on a hefty ST profit.
As far as ENTA is concerned, fundamentals have not changed and I am planning to add more if it drifts any further down which I doubt.
Ok fair enough but how do you explain, if you may, of such posters posting strong chance of downtrend without substantiating any basis other than the fact they have sold ?
You are really full of you know what. Just because you sold out on the ST top, to say it will keep going down is BS. You have proved to be just a trader and not an investor by any means.
General market. Look for LT. zalviso is a great product and will be approved.
Sold too soon huh ? Dream on. Lol
Nothing has changed on $ENTA other than due to market weakness. These 2 cents analysts are always behind the curve.
We might see $13+ closer to PDFUA date. Upon approval high teens
200 shares - no volume probably means nothing
I rather would buy ~120 shares of ENTA for 5k
I see stock climbing to $14-15 range closer to PDFUA date and spike to high teens upon approval.
Uptake of Zalviso in hospitals will beat expectations.
Being both neutral and having a ticket to 'space' doesn't compute lol
Good catch. Thanks for sharing.
I am hopeful that albeit recent insider sales the pps will continue uptrend as we go into year end. The silver lining is current pps is about 30% cheaper than last secondary.
ACAD - FWIW, I am quite bullish on the stock at these levels. Expect to see run up to $30+ pending EOY catalysts.
A better indicator would be funds positions change last quarter. Insiders would've have dumped en-masse recently if either they think it's fairly valued or for the risk you have highlighted.
However with ton of cash they will earn on HCV they might put that to use smartly and increase the EV
Must be Did you buy yet ?
You forgot to mention that it is still cheap
While this may appear to be logical the brokers who participate have lot to blame - overhyping that has pushed away lot of retail.
I do expect big pharma to do increased M&A due to attractive valuations though.
FWIW I took Dew's cue in terms of Gilead's valuation watermark which is ~$60 based on risk down the road to their HIV franchise. Will wait if not pass. I added more ENTA today.
I added ACAD as well to my LT position.
Dew, where do you see the bottom ? The irony of long term capital gains tax advantage is all but evaporated when the principal itself is at jeopardy. As there are apparent strength in any sector, I question the 'money is being rotated' theory as well.
I guess if investors are going all cash, they have to make it work at some point and other than stocks where else they can go.
One site that provides fair amount of chart & other indicator information:
http://finviz.com/quote.ashx?t=enta&ty=c&ta=1&p=d
Good point but let's not forget Enanta market cap is way cheaper than Gilead with HCV pipeline as good and probably better than Gilead's.
Enanta is one of few biotechs that is positioned well for both growth and profitability not to mention a potential B/O candidate down the road.
I am LT investor; so the volatility I see today is great opportunity to add quality stocks.
I think we will base around $35 to $36 for a while until NDA is filed. I added more today, FWIW
Cramer today morning in CNBC talked about BMY being another co closer to competing with Gilead on Hep C tx.
Could he not heard of ABBV/ENTA ? Bit surprised.
If Gilead hits $65 I will be a buyer FWIW
There are enough holes on their trial outcomes than on cheesecloth. And they are all leaking - going to be Pretty Rough And Nasty lol
Correction: an '15 EPS of $8 would give $80 which was around the recent peak where insiders were dumping
Would you be a buyer at these level ? FPRX. T.I.A
Sales are irritating enough; now dups are getting to be big nuisance
Would it not be more profitable for Enanta to offer another private placement from such selling shareholders to other institutions ? Must be hard for big buyers to buy open market without jacking up the price.
I am here too ! Just quietly watching the stock to run up to $20+ by 3rd quarter this year.
It's 4:1 not 1:1 based 25 % share for ABBV of HCV market if you discount everything else for both cos